Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 WuXi PharmaTech 1Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

WuXi PharmaTech 1Q11

Manufacturing outpaces lab services growth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi PharmaTech

1Q Revenues: $93.6 million (+16%)

1Q Earnings: $18.2 million (+17%)

Comments: Laboratory Services revenues grew 12% and Manufacturing Services were up 35% for the quarter. Manufacturing growth was driven by ramp-up of large-scale commercial manufacturing and increased demand for clinical trial materials. Gross margins in manufacturing rose from 19.9% to 26.7%, while Laboratory Services’ gross margins dropped from 41.4% to 39.6% due to higher labor costs, Chinese currency appreciation against the dollar, and depreciation expenses from expansion investments. Exchange rates accounted for $1.2 million of the quarter’s earnings.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics